• Citer

Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.

par Van Laethem, Jean-Luc ;Van Maele, Ph;Verslype, Chris;Polus, Marc;Demols, Anne ;Houbiers, Ghislain;Caenepeel, P.;Leleux, A.;Vermaut, R R;Van Cutsem, Eric;Peeters, Marc
Référence Oncology, 67, 5-6, page (338-343)
Publication Publié, 2004

Article révisé par les pairs

• Détails
• Contenu

Titre:	Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.
Auteur:	Van Laethem, Jean-Luc; Van Maele, Ph; Verslype, Chris; Polus, Marc; Demols, Anne; Houbiers, Ghislain; Caenepeel, P.; Leleux, A.; Vermaut, R R; Van Cutsem, Eric; Peeters, Marc
Informations sur la publication:	Oncology, 67, 5-6, page (338-343)
Statut de publication:	Publié, 2004
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adenocarcinoma -- drug therapy -- secondary
	Adult
	Aged
	Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
	Belgium
	Deoxycytidine -- administration & dosage -- analogs & derivatives
	Disease-Free Survival
	Drug Administration Schedule
	Female
	Humans
	Male
	Middle Aged
	Pancreatic Neoplasms -- drug therapy -- pathology
	Quinazolines -- administration & dosage
	Survival Analysis
	Thiophenes -- administration & dosage
	Treatment Outcome
Note générale:	Clinical Trial
	Clinical Trial, Phase II
	Journal Article
	Multicenter Study
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0030-2414
	info:doi/10.1159/000082916
	info:pii/82916
	info:scp/13844307892
	info:pmid/15713988